Marlborough

Earlier this year, before the coronavirus pandemic upended every corner of society and the economy, the COO of marketing agency Vision Advertising in Westborough had a regular checkup scheduled for March – one she nearly skipped.

California’s Revance Therapeutics has secured a tax increment financing agreement with Marlborough to cover a planned $115-million new construction with the company committing to the creation of 76 jobs.

Marlborough medical device manufacturer Boston Scientific has voluntarily recalled the unused inventory of one of its aortic valve systems and announced it will discontinue the product.

Novaya, a Boston real estate firm, has again turned to Marlborough for its investment portfolio, this time paying $16.7 million for an office building on Felton Street.

Marlborough medical technology company Hologic’s Genius Digital Diagnostics System is now approved by European regulators, having received its CE mark, the company announced on Tuesday.

Marlborough drugmaker Phio Pharmaceuticals has ended the third quarter of the year with $16.9 million on hand as it ramps up its research and development of its cancer therapy technology.

Walking assistance device manufacturer ReWalk Robotics, based in Marlborough, reported a $3.3 million net loss in the company’s third quarter, an improvement incrementally from a $3.4-million loss reported during the same quarter last year. 

In Central Mass., the restaurant industry is more developed in places like Worcester, Sturbridge and Marlborough, which have eschewed the state liquor license cap law in favor of having unlimited bars and eateries in their communities.

From the high-end Natick Mall to Solomon Pond Mall to the Mall at Whitney Field and elsewhere, retail plazas already struggling with closing chains are now facing an even more uncertain future because of the pandemic.

Marlborough medical technology device company Hologic reported $493.6 million in profits for the company’s fourth quarter, a massive 499% increase from the $123.5 net income loss reported during the same period last year, almost exclusively on the strengths of its coronavirus testing products.